Inceptionr LLC Makes New Investment in Illumina, Inc. $ILMN

Key Points

• Inceptionr LLC opened a new Q3 position in Illumina, buying 10,917 shares worth about $1.04 million.
• Institutional ownership is high at 89.42%, with several funds (Generali, Aaron Wealth, Douglas Lane, Nordea) adding to stakes while insiders have made small sales (insiders now own 0.17%).
• Analysts are mixed—6 Buy, 10 Hold, 2 Sell—giving an average Hold rating and $129.69 price target; Illumina recently beat EPS ($1.35 vs. $1.26) and set FY2026 guidance of $5.05–$5.20.

Inceptionr LLC bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,917 shares of the life sciences company's stock, valued at approximately $1,037,000.

Several other hedge funds have also modified their holdings of ILMN. Generali Asset Management SPA SGR lifted its holdings in Illumina by 51.6% in the third quarter. Generali Asset Management SPA SGR now owns 22,249 shares of the life sciences company's stock valued at $2,113,000 after acquiring an additional 7,574 shares during the period. Aaron Wealth Advisors LLC grew its stake in shares of Illumina by 342.6% during the 3rd quarter. Aaron Wealth Advisors LLC now owns 10,476 shares of the life sciences company's stock worth $995,000 after purchasing an additional 8,109 shares during the period. Douglas Lane & Associates LLC grew its stake in shares of Illumina by 6.6% during the 3rd quarter. Douglas Lane & Associates LLC now owns 307,609 shares of the life sciences company's stock worth $29,214,000 after purchasing an additional 18,914 shares during the period. Elo Mutual Pension Insurance Co purchased a new position in shares of Illumina in the 3rd quarter valued at about $2,319,000. Finally, Nordea Investment Management AB lifted its stake in shares of Illumina by 148.6% in the third quarter. Nordea Investment Management AB now owns 32,657 shares of the life sciences company's stock valued at $3,024,000 after purchasing an additional 19,519 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently commented on ILMN shares. JPMorgan Chase & Co. decreased their price objective on shares of Illumina from $130.00 to $120.00 and set a "neutral" rating on the stock in a report on Friday, February 6th. Guggenheim increased their target price on shares of Illumina from $144.00 to $170.00 and gave the company a "buy" rating in a report on Monday, January 26th. Barclays lifted their price target on shares of Illumina from $100.00 to $110.00 and gave the company an "underweight" rating in a research report on Monday, December 15th. Stifel Nicolaus boosted their price target on Illumina from $135.00 to $155.00 and gave the stock a "buy" rating in a research note on Tuesday, January 20th. Finally, Canaccord Genuity Group raised their price objective on Illumina from $130.00 to $150.00 and gave the company a "hold" rating in a research note on Monday, January 26th. Six investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $129.69.

Insider Buying and Selling

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the sale, the senior vice president owned 16,321 shares in the company, valued at approximately $1,896,173.78. This represents a 12.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Scott M. Davies sold 323 shares of the firm's stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the transaction, the insider directly owned 17,887 shares of the company's stock, valued at $2,434,241.83. The trade was a 1.77% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.17% of the stock is currently owned by corporate insiders.

Illumina Stock Performance

Shares of ILMN opened at $124.28 on Tuesday. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $155.53. The stock has a market cap of $19.00 billion, a P/E ratio of 22.80, a PEG ratio of 2.38 and a beta of 1.45. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55. The company has a 50-day moving average of $134.17 and a two-hundred day moving average of $119.55.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. During the same period in the prior year, the business earned $0.95 earnings per share. The company's quarterly revenue was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, research analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.